Literature DB >> 2807874

Natural killer activity in hyperprolactinemic patients.

L Matera1, E Ciccarelli, A Cesano, F Veglia, C Miola, F Camanni.   

Abstract

Several pieces of evidence suggest the existence of a relationship between neuroendocrine and immune systems. Prolactin (PRL) has been demonstrated to modulate some immune responses and its influence seems to be permissive or inhibitory depending on its concentration. Previous studies have reported a reduced natural killer (NK) cell function in patients with hyperprolactinemia. In 36 patients (34 females and 2 males, aged 14-46 years) with hyperprolactinemia (mean +/- SEM PRL 142.2 +/- 42.1 micrograms/l) of tumorous (19 patients) and functional (17 patients) origins, NK activity of peripheral blood lymphocytes (PBL) was studied. Patients had NK cell activity against the K562 cell line which did not differ from that of lymphocytes from 36 age- and sex-matched healthy donors (mean +/- SEM lytic units (LU) 619.0 +/- 103.0 and 531.9 +/- 52.6 respectively). No correlation between PRL levels and LU values was found (r = 0.28). When patients with tumors or functional hyperprolactinemia were separately analysed no difference was found between these two groups (mean +/- SEM LU 690.0 +/- 117.7 vs. 606.0 +/- 148.8). In conclusion, our data demonstrate that neither the elevated PRL levels nor the PRL-secreting tumor per se interfere with the NK system of hyperprolactinemic patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807874     DOI: 10.1016/0162-3109(89)90067-2

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  5 in total

1.  Relationship between 17-beta-estradiol and prolactin in the regulation of natural killer cell activity during progression of endometriosis.

Authors:  M Provinciali; G Di Stefano; M Muzzioli; G G Garzetti; A Ciavattini; N Fabris
Journal:  J Endocrinol Invest       Date:  1995-09       Impact factor: 4.256

Review 2.  The role of prolactin in the pathogenesis of autoimmune disease.

Authors:  Istvan Berczi
Journal:  Endocr Pathol       Date:  1993-12       Impact factor: 3.943

3.  Absence of prolactin gene expression in colorectal cancer.

Authors:  A J Wood; C M Thomas; K R Baumforth; J R Flavell; K W Scott; R H Grace; J G Williams; M R Holland; R Dunn; A G Jacobs; A Harrison; S Brun; N Plessis; P G Murray
Journal:  Mol Pathol       Date:  1999-06

4.  The effect of prolactin and bromocriptine on human peripheral immune status.

Authors:  P Kadioglu; O Açbay; G Demir; N Gazioglu; S Gundogdu
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

5.  Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient.

Authors:  A Vidaller; F Guadarrama; L Llorente; J B Méndez; F Larrea; A R Villa; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.